Weiguo Su

机构：Tamedia (Switzerland), State Administration of Foreign Exchange · ORCID：0000-0002-6482-3300

发表论文 152 篇 · 总被引 2746 次 · h-index 23

代表论文

• Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET -amplification ( MET amp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. (2025 · Journal of Clinical Oncology · 被引 9)
• Discovery of HMPL-306 (Ranosidenib), a New Potent and Selective Dual Inhibitor of Mutant IDH1 and 2 in Clinical Development for Cancer Treatment (2025 · ACS Medicinal Chemistry Letters · 被引 9)
• Sovleplenib in patients with primary or secondary warm autoimmune haemolytic anaemia: results from phase 2 of a randomised, double-blind, placebo-controlled, phase 2/3 study (2025 · The Lancet Haematology · 被引 8)
• HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 study (2025 · Med · 被引 7)
• Mussel-inspired oxidized sodium alginate/cellulose composite sponge with excellent shape recovery and antibacterial properties for the efficient control of non-compressible hemorrhage (2024 · International Journal of Biological Macromolecules · 被引 7)
• Efficacy and safety of tazemetostat, an EZH2 inhibitor, in Chinese patients with relapsed/refractory follicular lymphoma: a multicentre, single-arm, phase 2 study (2025 · EClinicalMedicine · 被引 5)